Tuesday, 24 August 2021

Anti-Fungal Treatment Market – Insights on Upcoming Trends 2027

 The global anti fungal treatment market is expected to register a CAGR of6.35% during the forecast period and is expected to hit USD 25,764.67 million by 2027.

Fungi are defined as microorganisms that can stay alive in a wide array of environments. Fungi can lead to diverse infections in the human body ranging from superficial skin to systemic that enters the body through inhalation. These infections occur in the human body, usually due to high exposure to unhygienic environments of fungus or due to low immune systems.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10602 

The most common fungal infections include ringworm, athlete’s foot, and fungal nail infection Furthermore, the increasing incidence of infections such as mucormycosis, candidiasis, and others are expected to propel market growth. Furthermore, anti fungal drugs restrict fungal microorganisms from growing on the host cell and eliminate the occurrence of fungal infection. Thus, the availability of diverse anti fungal drugs for the treatment of fungal infection and over-the-counter drugs for the treatment of dermal infection is positively influencing the anti fungal drug market growth.

Segment Analysis

The global anti fungal treatment market has been divided based on drug class, therapeutic indication, pathogen, and end user.The market, based on drug class, has been segregated into azoles, echinocandins, polyenes, allylamines, pyrimidines, and others.

Based on therapeutic indication,the anti fungal treatment market has been divided intotherapeutic indications, has been segmented into systemic, candidiasis, cryptococcosis, prophylactic use of anti fungals, and coccidioidomycosis.

Based on pathogen, the anti fungal treatment market has been divided into Candida, Aspergillus, Cryptococcus, Coccidioides immitis, Zygomycetes, Trichophyton, others.On the basis of end user, the market is bifurcated into hospitals and clinics, dermatology clinics, and others.

Regional Analysis

The global anti fungal treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa. The 40.97% market share of the Americas can be attributed to the high prevalence of anti fungal diseases, research spending, and the rapid adoption of advanced treatment in the region. The availability of a large research budget is anticipated to increase the grants for researchers to develop novel products for the anti fungal treatment market.

Europe is projected to exhibit significant growth during the forecast period due to a higher number of patients and the availability of diagnostic and treatment facilities in the region.The accessibility to advanced treatment facilities, rising government initiatives to promote research to find a cure to the increasing number of cases, and growing healthcare expenditure are driving the growth of the anti fungal treatment market in the region.

Asia-Pacific is expected to be the fastest-growing regional market in anti fungal treatment, mainly due to increasing R&D funding by developing countries such as China and India for the availability of basic treatments.The market for anti fungal treatment is growing at a significant rate in the Middle East & Africa due to the increasing number of companies and subsidiaries in the region offering treatment options.

Key Findings of the Study

  • The global anti fungal treatment market was valued at USD 15,835.52 millionin 2019 and is projected to register a CAGR of6.35% during the assessment period.
  • The Americas accounted for the largest share of the global market due to the rising prevalence of anti fungal diseases, research spending, and the rapid adoption of advanced treatment in the region.
  • Based on drug class, the azoles segment accounted for the largest market share of 41.7% in 2019
  • On the basis of ther apeutic indication, the candidiasis segment is expected to register the fastest growth at a CAGR of 6.64% during the forecast period
  • By pathogen, the candida segment accounted for the largest market share with a value of USD 8,176.20 million in 2019
  • Based on end user, the hospitals & clinics segment accounted for the largest market share with a value of USD 7,300.92 million in 2019
  • Pfizer Inc. (US), Novartis International AG (Switzerland), Sanofi S.A.(France), Merck KGaA (Germany), Bayer AG (Germany)are the key market players.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/anti-fungal-treatment-market-10602 

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Monday, 23 August 2021

Global Cerebral Vascular Stent Market size and forecast, 2020-2027

 According to MRFR analysis, the global cerebral vascular stentmarket is expected to register a CAGR of~9.0% from 2021 to 2027.

The global cerebral vascular stentmarket is driven by several factors, such asthe rising prevalence of cerebral vascular diseases and the boominggeriatric population.According to the World Stroke Organization (WSO)’s Global Stroke Fact Sheet 2019, 13 million new cases of stroke are diagnosed globally every year, and over 80 million people who have experienced a stroke are currently living. Furthermore, according to a report published by Mayo Clinic, the US, in May 2019, the most powerful non-modifiable risk factor for incident stroke is aging, and the risk doubles every ten years after the age of 55. Around three-quarters of all strokes occur in those over the age of 65. The frequency of incident strokes in the older populationis likely to growas the number of people aged 65 years rise.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9147 

The key players are involved in new product launches, strategic agreements, and acquisitions to strengthentheir market positions. For instance,in August 2018, Boston Scientific (US) announced an agreement to acquire VENITI, Inc. (US), specializing in venous stent systems. New product approvals by the FDA are supplementing the market growth. For instance, in May 2019, Stryker (US) announced the FDA approval of its brain aneurysm stent system called Neuroform Atlas.

Regional Analysis

North America is expected to dominate the cerebral vascular stentmarket in 2021, owing to the increasing health awareness, rising cerebrovascular disorders, technological developments in healthcare applications, and the presence of key players across the region. According to the Brain Aneurysm Foundation data for 2019, an estimated 6.5 million persons in the United States have an unruptured brain aneurysm, or around one in every 50 people. Each year, about 30,000 people in the United States have a brain aneurysm rupture.       

In Europe, the increasing base of the target patient population, namely elderly persons (over the age of 65) and increasing cerebral vascular disorders in the region, are expected to drive the market growth during the study period. According to a report published in July 2020 by King’s College London, by 2047, there will be 2.5 million cases of stroke in Europe, which is a 23% increase from 2017 data.

Asia-Pacific is anticipatedto be the fastest-growing regional market in the forecast period due to factors such asincreasing awareness of clinical outcomes, large population base, rise in geriatric population, and booming cerebral vascular disorders. According to a report by University of Indonesia in November 2020, China had the highest prevalence of stroke in Asia with 1114.8/100 000 persons.

The rest of the world comprises Middle East, Africa, and Latin America. Due to the high rate of acceptance of modern medical devices and the rapid expansion of the healthcare industry in these regions, the cerebral vascular stent market is projected to be a lucrative market in the near future.  

The global cerebral vascular stentmarket has been segmented into type and end user.

By type, the market has been segregated into tantalum,stainless steel, and nitinol. The nitinol segment is expected to hold a considerable market share in 2021due to its superior characteristics and wide applications in stents.

Based on end user,the cerebral vascular stentmarket is classified intohospitals, and ambulatory surgical centers. Hospitals held the largest market share in 2020 due toincreasing cerebrovascular disorders across the globe and the need for medical assistance for the same.

Key Players

Some of the key players in the global cerebral vascular stentmarketareStryker Corporation (US), Boston Scientific Corporation (US), Johnson & Johnson Services, Inc. (US), Terumo Corporation (Japan), Cook Medical (US), Penumbra, Inc. (US), Medtronic plc (Ireland), Acandis GmbH (Germany), Phenox GmbH (Germany), and MicroPort Scientific Corporation (China)among others.

Segmentation

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cerebral-vascular-stent-market-9147 

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Central Nervous System Biomarkers Market Growth, Trends and Value Chain 2020-2027

 According to MRFR analysis, the global CNS biomarkers market is expected to register a CAGR of~13.0%from 2021 to 2027and hold a value of over ~USD 7,500 million by2027.

The global CNS biomarkers market is driven by several factors, such astechnological advancements, an increase in the use of biomarkers inthe diagnosis of neurodegenerative diseases, increasing research and development, and successful clinical trials.According to Alzheimer’s Disease International, in 2020, over 50 million people have dementia, where CNS disorders help in the diagnosis and prognosis of the disorders. Furthermore, recent technologies such as genomics and proteomics, and imaging technologies, several new biomarkers are being developed.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9140 

The key players are involved in new product launches, strategic agreements, and joint ventures to augment their market positions. For instance, in September 2020, Siemens Healthineers (Germany) announced a strategic collaboration with Novartis Pharma AG (Switzerland) for biomarker development for Multiple Sclerosis. Furthermore, new product approvals by the FDA are supplementing the market growth. For instance, in May 2019, the N170 CNS biomarker letter of intent was accepted by the FDA for autism spectrum disorder, submitted by Roche (Switzerland) for approval.

Regional Analysis

North America is expected to dominate the CNS biomarkers market in 2021, owing to the growing geriatric population, the adoption of the latest technologies for CNS disorder treatment, and key industry players across the region. According to the US Census Bureau, the country .constitutesaround 34% of the population aged 65 andolder; this number has increased by 3.2% over a year. Among the different regions in the Americas, Maine ranks first with the highest geriatric population. This is increasing the demand for CNS biomarkers across the region sinceagingincreases the risks of brain disorders and other CNS disorders. Furthermore, companies and research institutes are constantly innovating and discovering new technologies and biomarkers. This is supported by the presence of leading key players within the region as well as increasing R&D expenditure. For instance, as of August 2020, USD 23.1 million was funded for brain-related clinical and cancer control research in the US, according to the American Cancer Society.     

In Europe, the increase in demand for personalized/precision medicine and the prevalence of neurological diseases in Europe are driving the CNS biomarkers market in the region. According to the report published in October 2020, in Europe, neurological disorders ranked third after cardiovascular diseases and cancer. Furthermore, another report published in July 2020 by King’s College London, by 2047, there will be 2.5 million cases of stroke in Europe, which is a 23% increase from 2017 data.

Asia-Pacific is expected to be the fastest-growing regional market in the forecast period due to factors such asa large customer base, high prevalence of CNS disorders, and improving healthcare infrastructure. China accounts for the highest number of stroke cases in the world, with 354 cases per 100,000 people in 2016, according to a report published in The Lancet in March 2019; this shows the immense application of CNS biomarkers in the region.

The rest of the world includes the Middle East, Africa, and Latin America. These regions are also facing an increase in neurological disorders, which is driving the CNS biomarkers market. For instance, according to a report from Alzheimer’s Disease International 2020, an estimated 6% of the 15 million older people (above the age of 50 years) in Brazil.  

Segmentation

The global CNS biomarkers market has been segmented into type, application, and end user.

By type, the market has been segregated into safety biomarker,efficacy biomarker, validation biomarker, and others. The safety biomarker segment is expected to hold a considerable share of the market in 2020due to its importance in clinical trials. The majority of the clinical trials fail due to safety and toxicity issues.

Based on application, the global CNS biomarkers market has been classified intodrug discovery & development, personalized medicine,and others. Personalized medicine witnessed high growth as the emphasis on personalized medicine increases due to more effectiveness and risk of minimal side effects than present treatments.

Based on end user,the CNS biomarkers market is classified intodiagnostic labs, hospitals&clinics and research centers. Diagnostic Labs held asignificantmarket share in 2020 due toincreasing neurological disorders across the globe and the need for diagnosis for the same.

Key Players

Some of the key players in the global CNS biomarkers marketareThermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), and Acumen Pharmaceuticals Inc. (US) amongothers.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/central-nervous-system-biomarkers-market-9140 

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Global Ophthalmic Drugs Market size and forecast, 2020-2027

 Market Highlights

Market Research Future (MRFR) studied the global ophthalmic drugs market 2021 for the review period till 2025. As per MRFR assessment, the global market of ophthalmic drugs is anticipated to register 5.1% CAGR over the forecast term. By 2025, the ophthalmic drugs market value can touch USD 29.46 Bn.

Drivers and Restrains Impacting Ophthalmic Drugs Market 

Ophthalmic drugs are used in the treatment of eye infection and other types of eye conditions. The growing prevalence of ophthalmic diseases, such as; age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema (DME), myopic choroidal neovascularization, and retinal vein occlusion (RVO), are potential threats to an individual’s sight.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5753 

The expansion of the global ophthalmic drugs market can be influenced by surge in investments in the development of novel drugs and escalation of funding for research on the formulation of ophthalmic drugs. In addition, the surging incidences and ongoing prevalence of eye-related disorders are other causes are expected to fuel the ophthalmic drugs market growth. The growing relationship among key companies can influence the ophthalmic drugs market and churn-up high revenue. For instance, Johnson & Johnson Surgical Vision, Inc. entered into a research collaboration with the Singapore Eye Research Institute (SERI) and National Eye Centre (SNEC) to tackle myopia. In addition, the Essilor signed a new research agreement Laas-CNRS laboratory for five years. Other major companies operating in the ophthalmic drugs market are involved in product launch, strategic acquisitions, collaborations to improve their global position.

Segmental Analysis

The Global Ophthalmic Drugs Market has been segmented based on  product type, dosage form, indication, drug class, and region.

The global ophthalmic drugs market, on the basis of dosage form, has been segmented into eye ointments, gels, eye solutions, capsules & tablets, eye drops, others.

The global ophthalmic drugs market, on the basis of drug class, has been divided into anti-glaucoma, anti-inflammatory, antibiotics, and others.

The global ophthalmic drugs market, based on product type, has been divided into prescription drug and over the counter (OTC) drug.

The global ophthalmic drugs market, on the basis of  indication, has been segmented into glaucoma, allergy, dry eye, and others.

Regional Overview

Due to the increasing number of geriatric individuals and the involvement of major existing players in the region, the ophthalmic drugs industry in the Americas is expected to dominate the eye drugs market. In addition, the emergence of patient population , increased incidence of eye diseases, well-developed infrastructure , high healthcare spending are also projected to lead to the increasing development of the regional sector.

The European demand for ophthalmic drugs has seen substantial development which can be due to the growing incidence of eye diseases. Owing to the growing pool of eye-related patient population and the expansion of healthcare services anticipated to fuel demand growth, the Asia-Pacific ophthalmic drugs market is estimated to have a steady growth rate during the forecast period.

The Middle East & Africa ophthalmic drugs industry is predicted to account for the least share of the global demand owing to poor disposable per capita income in the area.

Competitive Dashboard

The major Players operating in the Global Ophthalmic Drugs Market are  Allergan Plc, F. Hoffmann-La Roche AG, Novartis AG, Bausch Health Companies Inc., Pfizer Inc., Bayer AG, Merck & Co., Inc., Aerie Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ophthalmic-drugs-market-5753 


About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Medical Tricorder Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

 Market Highlights

Medical device used by the consumer to self-diagnose medical condition is known as a medical tricorder. It takes basic vital measurement like heart rate and body temperature within seconds. Major functions of a medical tricorder are to monitor health of a person, summarize patient’s health, diagnose disease and take health measurements. Furthermore, rapid development in technology, increasing government support for research & development, changing lifestyle, and many adverse effects of the present diagnostic methods expected to fuel the market growth during the forecast period.

Medical Device Industry is flourishing across the globe owing to an increasing demand for technologically advanced devices, extensive use of smart medical devices, and overall improvement in healthcare sector. Various smart devices are used to determine the heart rate, glucose levels in the body, and other parameters.

Global medical tricorder market is expected to reach USD 5.4 billion in 2023 from USD 2.5 billion in 2016 with a CAGR of approximately 6.7% during the forecast period.

However, these types of devices has to pass all the regulatory standards and rules, which increases the approval time. The average approval time for the medical diagnostic device may vary from 5-8 years. This long approval time, high cost of the research & development and devices may hamper the market growth during the corresponding period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1220  

The demand of medical tricorder is increasing because of an increase in the demand medical tricorder among health care providers, helping them to diagnose patient’s health condition, increasing outpatient services in the hospitals, increase in patient pool suffering from diabetes, and cardiovascular diseases, and demand for new technology for diagnoses and monitoring.

According to findings from the WHO, in 2014, approximately 422 million people suffered from diabetes across the globe.

Global Medical Tricorder Market – Regional:

Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.

America is the largest market which is attributed to extensive use of medical tricorder by number of physicians in America. Increasing in patient pool, increase in outpatient services and concentration of major market players of medical tricorder in North America drive this market in America. North America is the largest market whose growth is attributed to an increase in patient pool, and demand for improved technology for diagnosis of ongoing health of a patient drive this market in America. According to the American Diabetes Association, in 2015, approximately 30.3 million Americans which is 9.4% of the American population were suffering from diabetes 

The European market is also growing continuously and slowly catching up with the American market in the near future. Emphasis for early diagnosis of disease condition and awareness regarding the use of tricorder. Extensive research in innovative product development, and adoption of new technologies in healthcare institutes such as hospitals & clinics, research institutes, clinical laboratories, diagnostics center and home care settings. QuantuMDx Group Ltd. is in Europe. It is one of the major market players for medical tricorder, thus favoring the opportunities for research and development activities in the field of medical devices and molecular diagnosis.

Asia-Pacific market is expected to show steady growth in the medical tricorder market during the forecasted period owing to the rising prevalence of chronic diseases such as obesity, diabetes, cardiovascular diseases, growing geriatric population, and development in healthcare sector. China and India are expected to be the emerging market in Asia Pacific, owing to the increasing number of patients diagnosed with chronic diseases, and high growth potentials supported by favourable macro-economic conditions.

Middle East & Africa show slow growth in this market owing to demand for primary care services for the diagnosis and treatment of chronic diseases, and rising awareness about preventive measures for various diseases, and increasing emphasis on women and child care.

Global Medical Tricorder Market: Company Analysis

Ibis Biosciences, Inc. provides molecular diagnostics, offers instruments and reagents to analyze DNA and RNA for clinical specialists and laboratory. In February 2016, the company won a USD 2,124,718 federal contract from the Defense Advanced Research Projects Agency, Arlington, Virginia for R&D.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-tricorder-market-1220


About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Global Endoscopy Device Market Show Steady Growth: Study 2027

 Market Highlights

The endoscopy device market is projected to grow at a CAGR of 6.30% during the forecast period 2019-2027. As per the endoscopy device market research report, the global market for endoscopy device is projected to grow rapidly. According to analysts, success of minimally invasive non-robotic surgery as well as increasing prevalence of chronic diseases will drive the market growth during the forecast period 2019-2027. The endoscopy device market research report offers a comprehensive analysis of the global endoscopy device market and its application, end user, therapy, treatments & procedures, types, and accessory & processors segments. The stringent regulatory policies along with complications caused by endoscopy products are the elements that could influence the endoscopy device market advancement throughout the forecast period 2019-2027. The endoscopy device market research report by expert analysts is developed to assist organizations in the endoscopy device market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1967 

Market Segmentation

The global endoscopy device market has been segmented based on application, end user, therapy, treatments & procedures, types, and accessory & processors. On the basis of application, the market for endoscopy device is segmented based on otoscopy, bronchoscopy, gastrointestinal endoscopy, mediastinoscopy, obstetrics/gynecology endoscopy, urology endoscopy, and arthroscopy. Additionally, the market on the basis of end users is segmented into gastroenterologists, general and pediatric surgeons, obstetricians-gynecologists (ob/gyns),critical care, and orthopedic surgeons. The global market for endoscopy device is also covered based on therapy segment which is further split into arthroscopy, cystoscopy, endoscopic retrograde cholangiopancreatography, gastroscopy, laparoscopy, sigmoidoscopy, ureteroscopy, and colonoscopy. On the basis of treatments and procedures, the market for endoscopy device is segmented based on abdominal, gynecologic and pelvic organ conditions, joint and orthopedic conditions, lung and airway conditions, upper gastrointestinal conditions, urinary system conditions, and lower gastrointestinal conditions. Additionally, the market on the basis of types, is segmented into capsule endoscopes, flexible endoscopes, robot-assisted endoscopes, surgical endoscopes, and rigid endoscopes. The global market for endoscopy device is also covered based on the accessory and processors segment which is further split into accessory and processors.

Major elements such as high costs associated with new product creation could obstruct the endoscopy device market growth. However, according to the endoscopy device market research report, expanding therapeutic capability of endoscopy instruments along with the rise in the incidence of cancer and obesity will propel growth throughout the forecast period 2019-2027. The endoscopy device market is set to register growth at a high CAGR owing to these key factors. The exploration of application, end user, therapy, treatments & procedures, types, and accessory & processors segments along with regional markets has been given in the global endoscopy device market research report. The research analysts studying the endoscopy device market have put out market forecasts in the endoscopy device market research report in order to support endoscopy device market-based companies. The endoscopy device market research report provides extensive understanding of the endoscopy device market based on the information and forecasts till 2027.

Regional Overview

North America, Europe, Asia Pacific and the rest of the world regional market for endoscopy device are predominantly covered in the global endoscopy device market research report. Country-level endoscopy device markets spread across North America – the United States, Canada, and Mexico are also covered in the report. In South America – Brazil and other country-level endoscopy device markets are covered in the report. In Asia-Pacific (APAC) region, the country-level endoscopy device markets covered are Japan, India, China, and others. The endoscopy device market research report also explores the regional market for endoscopy device present in Europe in the United Kingdom, France, Italy, Spain, and Germany, etc. The endoscopy device market research report also covers regional markets from the rest of the world alongside endoscopy device markets of Africa and the Middle East.

Competitive Landscape

Expanding therapeutic capabilities of endoscopy instruments are presumed to drive the endoscopy device market growth worldwide. The global endoscopy device market could be challenged by loss of sales due to strict approval processes, nevertheless, organizations in the endoscopy device market will carry the growth rate forward. The endoscopy device market research report presents company profiles of major companies active in the endoscopy device market globally. Furthermore, the global endoscopy device market report offers an all-inclusive analysis of the market collected from the endoscopy device market’s primary and secondary sources covering both decision makers and thought leaders. The endoscopy device market research report highlights such key areas assisting businesses operating in the endoscopy device market to build better growth strategies.

Industry News

Physicians Endoscopy and physicians from Gastroenterology Associates Fredericksburg and Mary Washington Healthcare are pleased to announce their three-way joint venture collaboration and open the Fredericksburg Endoscopy Centre. Both practitioners in the Gastroenterology Associates of Fredericksburg will conduct their procedures in the center as well as the six physicians who are part of the three-way joint venture. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/endoscopy-devices-market-1967 

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Peripheral Neuropathy Market – Insights on Upcoming Trends 2027

 Market Highlights

The global peripheral neuropathy market is predicted to touch USD 292.40 million at a 3.9% CAGR between 2019- 2025, reveals the new Market Research Future (MRFR) report. Peripheral neuropathy develops the moment the nerves in the body’s extremities like arms, feet, and hands are damaged. The symptoms rest on the nerve type affected. Some of its common causes include damage in peripheral nerves causing numbness and weakness in feet and hands, exposure to toxins, inherited causes, metabolic problems, infections, traumatic injuries, and mostly due to diabetes mellitus. This disorder can be of different types such as HIV/AIDS-associated peripheral neuropathy, idiopathic peripheral neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy (DPN).

Various factors are adding to the global peripheral neuropathy market share. These factors, as per the new MRFR report, include increasing innovations & advancements in peripheral neuropathy, rising awareness about peripheral neuropathy, and growing use of chemotherapy for cancer patients. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8485 

On the contrary, strict government regulations may limit the peripheral neuropathy market growth over the forecast period. 

Market Segmentation

The MRFR Report provides an inclusive segmental analysis of the global peripheral neuropathy market based on end user, treatment, and type. 

By type, the peripheral neuropathy market is segmented into HIV/AIDS-associated peripheral neuropathy, idiopathic peripheral neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy (DPN). Of these, the DPN segment will lead the market over the forecast period for its rising cases in youths having diabetes. The CIPN segment is predicted to grow at the fastest pace over the forecast period for increasing use of chemotherapy to treat cancer patients. 

By treatment, the peripheral neuropathy market is segmented into non-pharmacological therapies, pharmacological therapies, and others. Of these, the pharmacological therapies segment is predicted to dominate the market over the forecast period for these therapies being the primary treatment for peripheral neuropathy. 

By end users, the peripheral neuropathy market is segmented into ambulatory centers, hospitals and clinics, and others. Of these, hospitals and clinics will spearhead the market over the forecast period for the increasing awareness regarding the availability of advanced treatments in hospitals. The ambulatory centers, on the other hand, are predicted to grow at the fastest pace over the forecast period for the availability of advanced medical technology and specialized medical services. 

Regional Analysis 

Based on the region, the global peripheral neuropathy market report covers the recent trends and growth opportunities across Europe, the Americas, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will command the largest share in the market over the forecast period. Canada & the US are the top contributors in the region for the rising prevalence of diabetes and the presence of top key players. 

The peripheral neuropathy market in Europe is predicted to hold the second-largest share over the forecast period for the rising prevalence of cancer, increasing awareness, and the availability of peripheral neuropathy treatment options. 

The peripheral neuropathy market in the APAC region is predicted to grow at the fastest pace over the forecast period for the increasing geriatric population having chronic diseases such as cancer and diabetes. 

The peripheral neuropathy market in the MEA is predicted to have the smallest share over the forecast period for limited exposure to advancements in technology and limited healthcare infrastructure. 

Key Players

Key players profiled in the global peripheral neuropathy market report include RxFunction, Inc. (US), F. Hoffmann-La Roche Ltd. (UK), Dr. Reddy's Laboratories (India), Lupin Limited (India), Cipla Limited (India), Merck and Co. Inc. (US), GlaxoSmithKline plc (UK), Pfizer Inc (US), Eli Lilly and Company (US), Novartis AG (UK), Bristol Myers Squibb (US), and Abbott Laboratories (US). Industry players have incorporated strategies such as strategic alliances, mergers, acquisitions, geographical expansions, partnerships, product launches, and collaborations to create a foothold in the market. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/peripheral-neuropathy-market-8485 

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com